Ticker Launch
Sign inTry it free

Reverse merger · Completed · CBIO

Crescent Biopharma, Inc.

Reverse merger with GlycoMimetics, Inc. (GLYC)

Crescent Biopharma, Inc. merged into GlycoMimetics, Inc. (GLYC), a Nasdaq-listed clinical-stage biotech after its uproleselan Phase 2/3 study missed its primary endpoint, in a reverse merger that takes the private company public. The deal was announced on Oct 29, 2024 and closed on Jun 13, 2025. The combined company trades as Crescent Biopharma, Inc. (CBIO) on Nasdaq.

Crescent Biopharma develops oncology therapeutics, led by CR-001, a PD-1 x VEGF bispecific antibody, and a pipeline of novel antibody-drug conjugates studied as single agents and in combination with CR-001. An IND filing for CR-001 is planned for the fourth quarter of 2025.

Status
Completed
Private company
Crescent Biopharma, Inc.
Public company
GlycoMimetics, Inc. (GLYC)
Public company business before
Nasdaq-listed clinical-stage biotech after its uproleselan Phase 2/3 study missed its primary endpoint
Announced
Oct 29, 2024
Closed
Jun 13, 2025
Combined company
Crescent Biopharma, Inc. (CBIO)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other completed reverse mergers